Compounds as PCSK9 inhibitors

Novel compounds targeting PCSK9 function provide an effective means to lower LDL cholesterol, addressing the lack of small molecule inhibitors in current treatments for cardiovascular diseases, thereby reducing cardiovascular risks.

CN119080674APending Publication Date: 2024-12-06SHENGKE PHARMA JIANGSU LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411020784.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-01-17
Filing Date
2021-01-14
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current treatments for cardiovascular diseases associated with high levels of low-density lipoprotein cholesterol (LDL-C) lack effective small molecule inhibitors to target PCSK9, which are crucial for reducing LDL-C levels and mitigating cardiovascular risk.

Method used

Development of novel compounds that inhibit PCSK9 function or production, potentially formulated into pharmaceutical compositions, including combinations with statins, to treat PCSK9-mediated diseases.

Benefits of technology

The compounds effectively lower blood LDL cholesterol levels, addressing cardiovascular risks by down-regulating PCSK9 function and providing therapeutic benefits for a range of PCSK9-mediated conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080674A_ABST
    Figure CN119080674A_ABST
Patent Text Reader

Abstract

The present invention relates to compounds that are PCSK9 inhibitors. Compounds of Formula (I) (wherein the variables are defined in the specification), pharmaceutical compositions comprising the compounds, and methods and uses of the compounds or compositions in the treatment of PCSK9 mediated diseases, such as cardiovascular diseases are disclosed. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with application date of January 14, 2021, application number 202180009622.9, and invention name “New compounds as PCSK9 inhibitors”. Technical Field

[0002] The present invention belongs to the field of medicinal chemistry, and specifically discloses a compound of formula (I) (wherein the variables are defined below), a pharmaceutical composition comprising the compound, and a method and use of the compound or composition in treating PCSK9-mediated diseases such as cardiovascular diseases. Background Art

[0003] Cardiovascular disease that occurs in patients with high levels of low-density lipoprotein cholesterol (LDL-C) is the leading cause of death. Elevated levels of LDL-C are considered to be a major risk factor for the development of coronary artery disease (CAD) and atherosclerotic plaques in the arteries. When LDL-C decreases, cardiovascular risk decreases.

[0004] Loss-of-function mutations in the low-density lipoprotein receptor (LDLR) gene in patients with familial hypercholesterolemia (FH) are closely associated with high plasma LDL-C levels and premature CAD beginning in childhood. LDLR, located on the cell membrane, lowers plasma LDL-C concentrations by receptor-mediated uptake of LDL-C into cells.

[0005] One of the biggest advances in the lipid-lowering field over the past decade has been the development of a lipid-modulating therapy that targets proprotein convertase subtilisin / kexin type 9 (PCSK9), which binds to LDLRs and targets them for lysosomal degradation. This is due to increased transcription of PCSK9 and LDLRs following statin use, which results in a reduction in the lipid restriction of statins.

[0006] Therefore, it is expected that the amount of LDLR can be increased by inhibiting the production of PCSK9 or inhibiting the function of PCSK9, resulting in a decrease in the blood LDL cholesterol level.

[0007] From the above viewpoints, research on inhibiting the function of PCSK9 or inhibiting the production of PCSK9 is currently underway. For example, attempts to inhibit the function of PCSK9 with monoclonal antibodies directed against PCSK9 and inhibit the production of PCSK9 by RNA interference have been reported. However, for patients with cardiovascular diseases, effective small molecule inhibitors are needed to inhibit the function of PCSK9. Summary of the invention

[0008] The object of the present invention is to provide a novel compound which has the effect of lowering blood LDL cholesterol and can be used as an active ingredient of a drug. More specifically, the present disclosure provides a method for down-regulating the function of PCSK9.

[0009] In one aspect, the present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and mixtures thereof:

[0010]

[0011] in:

[0012] Ring A is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group or C 6-10 Aryl;

[0013] Ring B is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0014] L1 is selected from the group consisting of bonds, -O-, -C(O)-, -CR'R”-, -CR'R”-CR'R”-, or -CR’R”-CR’R”-CR’R”-;

[0015] L2 is selected from the group consisting of bonds, -C(O)-, -CR'R”-, -CR'R”-CR'R”-, or -CR’R”-CR’R”-CR’R”-;

[0016] Y is selected from O, S, NH or CH2;

[0017] R1 is selected from H, -C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0018] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0019] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)Ra 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0020] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0021] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0022] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NRb R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0023] m = 0, 1, 2, 3, 4 or 5;

[0024] n = 0, 1, 2, 3 or 4;

[0025] p = 0, 1, 2, 3, 4, 5, 6, 7 or 8;

[0026] q = 0, 1, 2, 3, 4 or 5;

[0027] And among them,

[0028] R' and R" are each independently selected from H, halogen, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0029] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0030] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0031] Among them, Y, R1, R2, R s1 , R s2 , R s3 and R s4 Each of which is optionally substituted with 1, 2 or 3 R groups, wherein R is independently selected from H, -OH, halogen, -NO2, carbonyl, -L-CN, -L-OR a 、-L-SR a 、-L-NR b R c 、-LC(O)R a 、-LC(S)R a 、-LC(O)OR a 、-LC(S)OR a 、-LC(O)-NR b R c 、-LC(S)-NR b R c 、-LOC(O)R a 、-LOC(S)R a 、-LN(R b )-C(O)-R a 、-LN(R b )-C(S)-R a 、-LS(O) x R a 、-LS(O) x OR a 、-LS(O) x NR b R c 、-LN(R b )-S(O) x -R a 、-LN(R b )-S(O) x -NR b R c 、-LN(R b )-C(O)OR a 、-LN(R b )-C(S)OR a 、-LOC 1-6 Alkylene-OR a 、-LC(O)-C 1-6 Alkylene-NR b R c 、-LN(R b )-C(O)-NR b R c 、-LN(Rb )-C(S)-NR b R c 、-LOC(O)-NR b R c 、-LOC(S)-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl; wherein the C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl are each further optionally substituted with one or more of the following groups:

[0032] -L-CN, -NO2, carbonyl, -L-OR a 、-L-SR a 、-L-NR b R c 、-LC(O)R a 、-LC(S)R a 、-LC(O)OR a 、-LC(S)OR a 、-LC(O)-NR b R c 、-LC(S)-NR b R c 、-LOC(O)R a 、-LOC(S)R a 、-LN(R b )-C(O)-R a 、-LN(R b )-C(S)-R a 、-LS(O) x R a 、-LS(O) x OR a 、-LS(O) x NR b R c 、-LN(R b )-S(O) x -R a、-LN(R b )-S(O) x -NR b R c 、-LN(R b )-C(O)OR a 、-LN(R b )-C(S)OR a 、-LOC 1-6 Alkylene-OR a 、-LC(O)-C 1-6 Alkylene-NR b R c 、-LN(R b )-C(O)-NR b R c 、-LN(R b )-C(S)-NR b R c 、-LOC(O)-NR b R c or-LOC(S)-NR b R c ;

[0033] L is selected from chemical bonds, -C 1-6 Alkylene-, -C 2-6 Alkenylene- or -C 2-6 Alkynylidene-;

[0034] x=0, 1 or 2.

[0035] In another aspect, the present disclosure provides a pharmaceutical composition containing a compound of the present disclosure and a pharmaceutically acceptable excipient.

[0036] In another aspect, the present disclosure provides pharmaceutical compositions containing a compound of the present disclosure and a pharmaceutically acceptable excipient, which also contain other therapeutic agents, such as statins.

[0037] In another aspect, the present disclosure provides the use of a compound of the present disclosure in the preparation of a medicament for treating and / or preventing a PCSK9-mediated disease.

[0038] In another aspect, the present disclosure provides a method of treating and / or preventing a PCSK9-mediated disease in a subject, comprising administering to the subject a compound of the present disclosure or a composition of the present disclosure.

[0039] In another aspect, the present disclosure provides a compound or composition of the present disclosure for use in treating and / or preventing a PCSK9-mediated disease.

[0040] In specific embodiments, the diseases described herein include atherosclerosis, dyslipidemia, hypertriglyceridemia, hypertension, heart failure, arrhythmia, low HDL levels, high LDL levels, sudden death, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia (including heterozygous and homozygous familial hypercholesterolemia), stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease, arterial occlusive disease, cerebral arteriosclerosis, cerebrovascular disease, myocardial ischemia, non-alcoholic fatty liver disease (NLLD), non-alcoholic steatohepatitis (NASH), and diabetic autonomic neuropathy.

[0041] Other objects and advantages of the present disclosure will be apparent to those skilled in the art from the following detailed description, examples and claims.

[0042] definition

[0043] Chemical Definition

[0044] Definitions of specific functional groups and chemical terms are described in more detail below.

[0045] When a numerical range is listed, it is intended to include every value and sub-range within that range. For example, "C 1-6 "Alkyl" is intended to include C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 and C 5-6 alkyl.

[0046] “C 1-6 "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 Alkyl groups are preferred. Exemplary C 1-6Alkyl includes: methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5) and n-hexyl (C6). The term “C 1-6 "Alkyl" also includes heteroalkyl groups in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents or 1 substituent. Conventional alkyl abbreviations include: Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3) or i-Bu(-CH2CH(CH3)2).

[0047] “C 2-6 "Alkenyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 Alkenyl is preferred. Exemplary C 2-6 Alkenyl includes: vinyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. The term “C 2-6 "Alkenyl" also includes heteroalkenyl groups in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkenyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0048] “C 2-6 "Alkynyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 Alkynyl is preferred. Exemplary C 2-6 Alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), hexynyl (C6), and the like. The term “C 2-6"Alkynyl" also includes heteroalkynyl groups, in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). Alkynyl groups may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0049] "-C 1-6 Alkylene-, -C 2-6 Alkenylene- or -C 2-6 "Alkyne-" refers to the above-defined "C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 "Alkynyl" divalent group.

[0050] “C 1-6 "Alkylene" refers to the removal of C 1-6 The other hydrogen of C alkyl forms a divalent group, and may be a substituted or unsubstituted alkylene. 1-4 Alkylene is particularly preferred. Unsubstituted alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), etc. Exemplary substituted alkylene groups, for example, alkylene groups substituted with one or more alkyl(methyl) groups, include, but are not limited to, substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3)2-), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-), and the like.

[0051] “C 2-6 "Alkenylene" means removing the C 2-6 In some embodiments, C 2-4Alkenylene is particularly preferred. Exemplary unsubstituted alkenylene groups include, but are not limited to, vinylene (-CH=CH-) and propenylene (e.g., -CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted alkenylene groups, for example, substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted vinylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propenylene (e.g., -C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)-CH=CH-, -C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like.

[0052] “C 2-6 "Alkynylidene" refers to the removal of C 2-6 The other hydrogen of the alkynyl group forms a divalent group, and may be a substituted or unsubstituted alkynylene group. 2-4 Alkyne is particularly preferred. Exemplary alkynyl groups include, but are not limited to, ethynyl (-C≡C-), substituted or unsubstituted propynyl (-C≡CCH2-), and the like.

[0053] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0054] “C 1-6 "Haloalkyl" means the above "C 1-6 Examples include monohalogenated, dihalogenated, polyhalogenated (including perhalogenated) alkyl groups. Monohalogen substituents may have one iodine, bromine, chlorine or fluorine atom in the group; dihalogen substituents and polyhalogen substituents may have two or more of the same halogen atoms or a combination of different halogens. Exemplary preferred haloalkyl groups include monofluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The haloalkyl group may be substituted at any available point of attachment, for example, with 1 to 5 substituents, 1 to 3 substituents or 1 substituent.

[0055] “C 3-7 "Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to 7 ring carbon atoms and zero heteroatoms. In some embodiments, C 3-6 Cycloalkyl is particularly preferred, and C 5-6Cycloalkyl is more preferred.Cycloalkyl also includes a ring system in which the above-mentioned cycloalkyl ring is fused with one or more aryl or heteroaryl groups, wherein the connection point is on the cycloalkyl ring, and in such a case, the number of carbons continues to represent the number of carbons in the cycloalkyl system. Exemplary cycloalkyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), etc. The cycloalkyl group can be optionally substituted by one or more substituents, for example, substituted by 1 to 5 substituents, 1 to 3 substituents or 1 substituent.

[0056] "3-11 membered heterocyclyl" refers to a group of a 3 to 11 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon. In heterocyclyls containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as the valence permits. In some embodiments, a 3 to 9 membered heterocyclyl is preferred, which is a group of a 3 to 9 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms. In some embodiments, a 3 to 7 membered heterocyclyl is preferred, which is a group of a 3 to 7 membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms. A 3 to 6 membered heterocyclyl is preferred, which is a group of a 3 to 6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms. A 4 to 6 membered heterocyclyl is preferred, which is a group of a 4 to 6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms. 5 to 6 membered heterocyclic groups are more preferably groups of 5 to 6 membered non-aromatic ring systems having ring carbon atoms and 1 to 3 ring heteroatoms. Heterocyclic groups also include ring systems in which the above-mentioned heterocyclic ring is fused with one or more cycloalkyl groups, wherein the connection point is on the cycloalkyl ring, or ring systems in which the above-mentioned heterocyclic ring is fused with one or more aryl or heteroaryl groups, wherein the connection point is on the heterocyclic ring; and in such a case, the number of ring members continues to represent the number of ring members in the heterocyclic ring system. Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to: aziridine, oxadiazine, thiorenyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to: azetidinyl, oxadiazine and thiodiazine. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to, hexahydrotriazinyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepane and thiepanyl.Exemplary 5-membered heterocyclyl groups fused to C6 aryl (also referred to herein as 5,6-bicyclic heterocyclyl) include, but are not limited to, dihydroindolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groups fused to C6 aryl (also referred to herein as 6,6-bicyclic heterocyclyl) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. The heterocyclyl group may be substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0057] 3 to 11 yuan of heterocyclic radicals also include spiro heterocyclic radicals, that is, two rings therein (for example, heterocycle and carbocycle) share a group of carbon atoms, wherein at least one ring is a heterocyclic radical as defined above. More specifically, spiro heterocyclic radical is a spiro ring formed by two 4-membered rings, two 5-membered rings, two 6-membered rings, a 4-membered ring and a 5-membered ring, a 4-membered ring and a 6-membered ring, or a 5-membered ring and a 6-membered ring, wherein at least one ring is a 4 to 6-membered heterocyclic radical as defined above. 4 to 6-membered heterocyclic radicals containing 1,2 or 3 O, N or S heteroatoms are preferred.

[0058] Specific examples of preferred heterocyclic groups include pyrrolinyl, imidazolidinyl, pyrazolidinyl, tetrahydropyranyl, dihydropyranyl, dihydrofuranyl, tetrahydrothiazolyl, dihydrothiazolyl, 2,3-dihydro-benzo[1,4]dioxolyl, indolinyl, isoindolinyl, dihydrobenzothiophene, dihydrobenzofuranyl, isodihydrobenzopyranyl, dihydrobenzopyranyl, 1,2-dihydroisoquinoline, 1,2,3,4-tetrahydroisoquinoline, 1,2,3,4-tetrahydroquinoline, 2,3,4,4a,9,9a-hexahydro-1H-3-azafluorene, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, benzo[1,4]dioxolane, 2,3-dihydro-1H-lk'-benzo[d]isoquinolyl, Thiazol-6-yl, 2,3-dibenzo[1,4]dioxin-1, dihydrobenzofuran, 2-oxoaziridine-1-yl, 2-oxoazetidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxopiperidin-1-yl, 2-oxoazepan-1-yl, 2-oxoazocantane-1-yl, 2-oxoazonane-1-yl, 2-oxoazepanonane-1-yl, 2-oxoazepanodecan-1-yl,

[0063] ] 1, 2, 4, 5, 6, 7, 8, 11, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, 65, 67, 68, 69, 71, 72, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92

[0059] “C6-10 "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having 6-10 ring carbon atoms and zero heteroatoms. In some embodiments, the aryl group has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, the aryl group has ten ring carbon atoms ("C 10 Aryl also includes ring systems in which the above aryl ring is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to refer to the number of carbon atoms in the aryl ring system. Aryl groups can be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0060] "5-10 membered heteroaryl" refers to a group of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as the valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. Heteroaryl also includes a ring system in which the above-mentioned heteroaryl ring is fused to one or more cycloalkyl or heterocyclic groups, and the point of attachment is on the heteroaryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the heteroaryl ring system. In some embodiments, 5-6 membered heteroaryl is particularly preferred, which is a group of a 5-6 membered monocyclic or bicyclic 4n+2 aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms. Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl), and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azacycloheptatrienyl, oxacycloheptatrienyl, and thiacycloheptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothienyl, isobenzothienyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indazinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolyl, isoquinolyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. The heteroaryl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0061] Specific examples of preferred heteroaryl groups include: pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl), pyranyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, oxazolyl, isoxazolyl, oxazolyl (1,2,4-oxazolyl, 1,3,4-oxazolyl, 1,2,5-oxazolyl), thiazolyl, thiadiazolyl (1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl).

[0062] "Carbonyl", whether used alone or in combination with other terms (eg, aminocarbonyl), is represented by -C(O)-.

[0063] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl groups as defined herein are optionally substituted.

[0064] Exemplary substituents on carbon atoms include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X - 、-N(OR cc )R bb , -SH, -SR aa 、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc 2. -CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2, -OC(=O)N(R bb )2.-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2, -C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NRbb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(R cc )2、-OP(R cc )3、-B(R aa )2、-B(ORcc )2. -BR aa (OR cc ), alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0065] Or the two geminal hydrogen atoms on the carbon atom are replaced by groups =O, =S, =NN (R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O)2R aa , =NR bb or = NOR cc replace;

[0066] R aa Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R aa The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0067] R bb Each of is independently selected from: hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa 、-P(=O)(R aa )2、-P(=O)2N(Rcc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl and heteroaryl, or two R bb The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0068] R cc Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R cc The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0069] R dd Each of is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2,-N(R ff )3 + X - 、-N(OR ee )R ff , -SH, -SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2, -OC(=O)N(R ff )2.-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2, -C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )OR ee 、-C(=NR ff )N(R ff)2, -OC(=NR ff )N(R ff )2.-NR ff C(=NR ff )N(R ff )2.-NR ff S02R ee 、-SO2N(R ff 2. -SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3.-OSi(R ee )3. -C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)2R ee 、-P(=O)(R ee )2.-OP(=O)(R ee )2.-OP(=O)(OR ee )2, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substituted, or two geminal R dd Substituents may combine to form =O or =S;

[0070] R ee Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substitution;

[0071] R ff Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R ff The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substitution;

[0072] R gg Each of is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3 + X-、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6Alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 Alkyl)3, -OSi(C 1-6 Alkyl)3, -C(=S)N(C 1-6 alkyl)2, C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1-6 Alkyl)2, -OP(=O)(C 1-6 Alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 carbocyclic group, C6-C 10 Aryl, C3-C7 heterocyclic, C5-C 10 heteroaryl; or two geminal R gg The substituents may combine to form =O or =S, wherein X- is a counter ion.

[0073] Exemplary substituents on nitrogen atoms include, but are not limited to, hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa、-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R attached to the nitrogen atom cc The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd substituted with a group, and wherein R aa , R bb , R cc and R dd As mentioned above.

[0074] Other definitions

[0075] The term "treat" as used herein relates to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which the term applies, or one or more symptoms of such a disorder or condition. The noun "treat" as used herein relates to the action of the verb treat, the latter being as just defined.

[0076] The term "pharmaceutically acceptable salt" as used herein refers to those carboxylates, amino acid addition salts of the compounds of the present disclosure which are suitable for use in contact with patient tissues within the scope of sound medical judgment, do not produce undue toxicity, irritation, allergic response, etc., are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use, including (where possible) zwitterionic forms of the compounds of the present disclosure.

[0077] The term "salt" refers to relatively non-toxic addition salts of inorganic and organic acids in combination with compounds of the present disclosure. These salts can be prepared in situ during the final separation and purification of the compound, or by separating the salts produced by the reaction of the pure free base form of the compound with a suitable organic acid or inorganic acid, respectively. As long as the compounds of the present disclosure are basic compounds, they can form a variety of different salts with various inorganic and organic acids. Although these salts must be pharmaceutically acceptable for animal administration, in practice it is usually necessary to first separate the pharmaceutically unacceptable salts of the basic compound from the reaction mixture, and then simply treat with an alkaline agent to convert it into the free base compound, and then convert the free base into a pharmaceutically acceptable acid addition salt. The acid addition salts of the basic compound are prepared by contacting the free base form with a sufficient amount of the desired acid in a conventional manner to form a salt. The free base can be regenerated by contacting the salt form with a base in a conventional manner and then separating the free base. The free base forms differ somewhat from their respective salt forms in certain physical properties, such as solubility in polar solvents. However, the salts are still equivalent to their respective free bases for the purposes of this disclosure.

[0078] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali metals and alkaline earth metal hydroxides or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, etc. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine.

[0079] Base addition salts of acidic compounds can be prepared by contacting the free acid form with a sufficient amount of the desired base in a conventional manner to form the salt. The free acid can be regenerated by contacting the salt form with an acid in a conventional manner and isolating the free acid. The free acid forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but for purposes of this disclosure, the salts are equivalent to their respective free acids.

[0080] Salts can be sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides and iodides prepared from inorganic acids. Examples of acids include hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, etc. Representative salts include: hydrobromate, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, mesylate, glucoheptonate, lactobionate, lauryl sulfonate and isethionate, etc. Salts can also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Representative salts include acetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, naphthoate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, etc. Pharmaceutically acceptable salts may include cations based on alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, etc., as well as non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. Also contemplated are salts of amino acids, such as argininate, gluconate, galacturonate, and the like (see, e.g., Berge SM et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977; 66: 1-19, incorporated herein by reference).

[0081] Exemplary pharmaceutically acceptable non-toxic esters of the disclosed compounds include: C1-C6 alkyl esters, wherein the alkyl group is straight or branched. Acceptable esters also include C5-C7 cycloalkyl esters and aryl alkyl esters (such as but not limited to benzyl esters). C1-C4 alkyl esters are preferred. Esters of the disclosed compounds can be prepared according to conventional methods, for example, March's Advanced Organic Chemistry, 5th edition, MB Smith & J. March, John Wiley & Sons, 2001.

[0082] Exemplary pharmaceutically acceptable non-toxic amides of the disclosed compounds include amides derived from ammonia, primary C1-C6 alkylamines and secondary C1-C6 dialkylamines, wherein the alkyl group is straight or branched. In the case of secondary amines, the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C1-C3 alkyl primary amines and C1-C2 dialkyl secondary amines are preferred. Amides of the disclosed compounds can be prepared according to conventional methods, for example, March's Advanced Organic Chemistry, 5th edition, MB Smith & J. March, John Wiley & Sons, 2001.

[0083] "Subjects" for administration include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.

[0084] "Disease," "disorder," and "condition" are used interchangeably herein.

[0085] As used herein, and unless otherwise indicated, the terms "treat," "treatment," "treat ...

[0086] Generally, an "effective amount" of a compound refers to an amount sufficient to elicit a target biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of the disclosed compounds may vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and symptoms of the subject. An effective amount includes a therapeutically effective amount and a prophylactically effective amount.

[0087] Unless otherwise specified, a "therapeutically effective amount" of a compound as used herein is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" can include an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic effect of other therapeutic agents.

[0088] Unless otherwise specified, a "prophylactically effective amount" of a compound as used herein is an amount sufficient to prevent a disease, disorder, or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder, or condition, or an amount to prevent the recurrence of a disease, disorder, or condition. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent that provides a prophylactic benefit in the process of preventing a disease, disorder, or condition when used alone or in combination with other agents. The term "prophylactically effective amount" may include an amount that improves overall prevention, or an amount that enhances the prophylactic effect of other prophylactic agents.

[0089] "Combination" and related terms refer to the simultaneous or sequential administration of the disclosed compounds and other therapeutic agents. For example, the disclosed compounds can be administered simultaneously or sequentially with the other therapeutic agents in separate unit dosage forms, or simultaneously with the other therapeutic agents in a single unit dosage form. Specific implementation plan

[0090] As used herein, "compounds of the present disclosure" refers to compounds of formula (I), formula (II-1), etc. as shown below, or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof.

[0091] Herein, compounds are generally named using standard nomenclature. It should be understood that, unless otherwise stated, compounds with asymmetric centers include all optical isomers and mixtures thereof. In addition, unless otherwise specified, all isomeric compounds included in the disclosure may appear in the form of Z and E with carbon-carbon double bonds. For compounds that exist in different tautomeric forms, one of the compounds is not limited to any specific tautomer, but is intended to cover all tautomeric forms.

[0092] In one embodiment, the present disclosure refers to a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and mixtures thereof:

[0093]

[0094] in:

[0095] Ring A is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group or C 6-10 Aryl;

[0096] Ring B is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0097] L1 is selected from the group consisting of bonds, -O-, -C(O)-, -CR'R”-, -CR'R”-CR'R”-, or -CR’R”-CR’R”-CR’R”-;

[0098] L2 is selected from the group consisting of bonds, -C(O)-, -CR'R”-, -CR'R”-CR'R”-, or -CR’R”-CR’R”-CR’R”-;

[0099] Y is selected from O, S, NH or CH2;

[0100] R1 is selected from H, -C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0101] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0102] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0103] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0104] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0105] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0106] m = 0, 1, 2, 3, 4 or 5;

[0107] n = 0, 1, 2, 3 or 4;

[0108] p = 0, 1, 2, 3, 4, 5, 6, 7 or 8;

[0109] q = 0, 1, 2, 3, 4 or 5;

[0110] And among them,

[0111] R' and R" are each independently selected from H, halogen, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0112] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0113] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0114] Among them, Y, R1, R2, R s1 , R s2, R s3 and R s4 Each of which is optionally substituted with 1, 2 or 3 R groups, wherein R is independently selected from H, -OH, halogen, -NO2, carbonyl, -L-CN, -L-OR a 、-L-SR a 、-L-NR b R c 、-LC(O)R a 、-LC(S)R a 、-LC(O)OR a 、-LC(S)OR a 、-LC(O)-NR b R c 、-LC(S)-NR b R c 、-LOC(O)R a 、-LOC(S)R a 、-LN(R b )-C(O)-R a 、-LN(R b )-C(S)-R a 、-LS(O) x R a 、-LS(O) x OR a 、-LS(O) x NR b R c 、-LN(R b )-S(O) x -R a 、-LN(R b )-S(O) x -NR b R c 、-LN(R b )-C(O)OR a 、-LN(R b )-C(S)OR a 、-LOC 1-6 Alkylene-OR a 、-LC(O)-C 1-6 Alkylene-NR b R c 、-LN(R b )-C(O)-NR b R c 、-LN(R b )-C(S)-NR b R c 、-LOC(O)-NRb R c 、-LOC(S)-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl; wherein the C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl are each further optionally substituted with one or more of the following groups:

[0115] -L-CN, -NO2, carbonyl, -L-OR a 、-L-SR a 、-L-NR b R c 、-LC(O)R a 、-LC(S)R a 、-LC(O)OR a 、-LC(S)OR a 、-LC(O)-NR b R c 、-LC(S)-NR b R c 、-LOC(O)R a 、-LOC(S)R a 、-LN(R b )-C(O)-R a 、-LN(R b )-C(S)-R a 、-LS(O) x R a 、-LS(O) x OR a 、-LS(O) x NR b R c 、-LN(R b )-S(O) x -R a 、-LN(R b )-S(O) x -NR b Rc 、-LN(R b )-C(O)OR a 、-LN(R b )-C(S)OR a 、-LOC 1-6 Alkylene-OR a 、-LC(O)-C 1-6 Alkylene-NR b R c 、-LN(R b )-C(O)-NR b R c 、-LN(R b )-C(S)-NR b R c 、-LOC(O)-NR b R c or-LOC(S)-NR b R c ;

[0116] L is selected from chemical bonds, -C 1-6 Alkylene-, -C 2-6 Alkenylene- or -C 2-6 Alkynylidene-;

[0117] x=0, 1 or 2.

[0118] Ring A

[0119] In one embodiment, Ring A is C 3-7 cycloalkyl; in another embodiment, ring A is a 3- to 7-membered heterocyclyl; in another embodiment, ring A is C 6-10 Aryl.

[0120] Ring B

[0121] In one embodiment, Ring B is C 3-7 cycloalkyl; in another embodiment, ring B is a 3- to 7-membered heterocyclyl; in another embodiment, ring B is C 6-10 Aryl; in another embodiment, Ring B is a 5- to 10-membered heteroaryl.

[0122] L1

[0123] In one embodiment, L1 is a bond; in another embodiment, L1 is -O-; in another embodiment, L1 is -C(O)-; in another embodiment, L1 is -CR'R"-; in another embodiment, L1 is -CR'R"-CR'R"-; in another embodiment, L1 is -CR'R"-CR'R"-CR'R"-.

[0124] L2

[0125] In one embodiment, L2 is a bond; in another embodiment, L2 is -C(O)-; in another embodiment, L2 is -CR'R"-; in another embodiment, L2 is -CR'R"-CR'R"-; in another embodiment, L2 is -CR'R"-CR'R"-CR'R"-.

[0126] Y

[0127] In one embodiment, Y is O; in another embodiment, Y is S; in another embodiment, Y is NH; in another embodiment, Y is CH2.

[0128] R1

[0129] In one embodiment, R1 is H; in another embodiment, R1 is -C(O)R a In another embodiment, R1 is -C(O)OR a In another embodiment, R1 is -C(O)NR b R c In another embodiment, R1 is C 1-6 Alkyl; in another embodiment, R1 is C 1-6 haloalkyl; in another embodiment, R1 is C 3-7 cycloalkyl; in another embodiment, R1 is a 3- to 7-membered heterocyclyl; in another embodiment, R1 is C 6-10 Aryl; in another embodiment, R1 is a 5- to 10-membered heteroaryl.

[0130] R2

[0131] In one embodiment, R2 is H; in another embodiment, R2 is C 1-6 Alkyl; in another embodiment, R2 is C 1-6 Halogenated alkyl.

[0132] R s1

[0133] In one embodiment, R s1 is H; in another embodiment, R s1 is halogen; in another embodiment, R s1 is -CN; in another embodiment, R s1 is -NO2; in another embodiment, R s1 For-OR a In another embodiment, R s1 For-SRa In another embodiment, R s1 For-NR b R c In another embodiment, R s1 -C(O)R a In another embodiment, R s1 -C(O)OR a In another embodiment, R s1 -C(O)NR b R c In another embodiment, R s1 C 1-6 Alkyl; in another embodiment, R s1 C 1-6 haloalkyl; in another embodiment, R s1 C 2-6 alkenyl; in another embodiment, R s1 C 2-6 Alkynyl; in another embodiment, R s1 C 3-7 Cycloalkyl; in another embodiment, R s1 is a 3- to 7-membered heterocyclyl; in another embodiment, R s1 C 6-10 Aryl; in another embodiment, R s1 It is a 5- to 10-membered heteroaryl group.

[0134] R s2

[0135] In one embodiment, R s2 is H; in another embodiment, R s2 is halogen; in another embodiment, R s2 is -CN; in another embodiment, R s2 is -NO2; in another embodiment, R s2 For-OR a In another embodiment, R s2 For-SR a In another embodiment, R s2 For-NR b R c In another embodiment, R s2 -C(O)R a In another embodiment, R s2 -C(O)OR a In another embodiment, R s2 -C(O)NR b Rc In another embodiment, R s2 C 1-6 Alkyl; in another embodiment, R s2 C 1-6 haloalkyl; in another embodiment, R s2 C 2-6 alkenyl; in another embodiment, R s2 C 2-6 Alkynyl; in another embodiment, R s2 C 3-7 Cycloalkyl; in another embodiment, R s2 is a 3- to 7-membered heterocyclyl; in another embodiment, R s2 C 6-10 Aryl; in another embodiment, R s2 It is a 5- to 10-membered heteroaryl group.

[0136] R s3

[0137] In one embodiment, R s3 is H; in another embodiment, R s3 is halogen; in another embodiment, R s3 is -CN; in another embodiment, R s3 is -NO2; in another embodiment, R s3 For-OR a In another embodiment, R s3 For-SR a In another embodiment, R s3 For-NR b R c In another embodiment, R s3 -C(O)R a In another embodiment, R s3 -C(O)OR a In another embodiment, R s3 -C(O)NR b R c In another embodiment, R s3 C 1-6 Alkyl; in another embodiment, R s3 C 1-6 haloalkyl; in another embodiment, R s3 C 2-6 alkenyl; in another embodiment, R s3 C 2-6 Alkynyl; in another embodiment, R s3 C3-7 Cycloalkyl; in another embodiment, R s3 is a 3- to 7-membered heterocyclyl; in another embodiment, R s3 C 6-10 Aryl; in another embodiment, R s3 It is a 5- to 10-membered heteroaryl group.

[0138] R s4

[0139] In one embodiment, R s4 is H; in another embodiment, R s4 is halogen; in another embodiment, R s4 is -CN; in another embodiment, R s4 is -NO2; in another embodiment, R s4 For-OR a In another embodiment, R s4 For-SR a In another embodiment, R s4 For-NR b R c In another embodiment, R s4 -C(O)R a In another embodiment, R s4 -C(O)OR a In another embodiment, R s4 -C(O)NR b R c In another embodiment, R s4 C 1-6 Alkyl; in another embodiment, R s4 C 1-6 haloalkyl; in another embodiment, R s4 C 2-6 alkenyl; in another embodiment, R s4 C 2-6 Alkynyl; in another embodiment, R s4 C 3-7 Cycloalkyl; in another embodiment, R s4 is a 3- to 7-membered heterocyclyl; in another embodiment, R s4 C 6-10 Aryl; in another embodiment, R s4 It is a 5- to 10-membered heteroaryl group.

[0140] m

[0141] In one embodiment, m=0; in another embodiment, m=1; in another embodiment, m=2; in another embodiment, m=3; in another embodiment, m=4; in another embodiment, m=5.

[0142] n

[0143] In one embodiment, n=0; in another embodiment, n=1; in another embodiment, n=2; in another embodiment, n=3; in another embodiment, n=4.

[0144] p

[0145] In one embodiment, p=0; in another embodiment, p=1; in another embodiment, p=2; in another embodiment, p=3; in another embodiment, p=4; in another embodiment, p=5; in another embodiment, p=6; in another embodiment, p=7; in another embodiment, p=8.

[0146] q

[0147] In one embodiment, q=0; in another embodiment, q=1; in another embodiment, q=2; in another embodiment, q=3; in another embodiment, q=4; in another embodiment, q=5.

[0148] Any technical solution or any combination thereof in any of the above embodiments can be combined with any technical solution or any combination thereof in the above embodiments. For example, any technical solution or any combination thereof of ring A can be combined with ring B, L1, L2, Y, R1, R2, R s1 -R s4 , m, n, p and q, etc. or any combination thereof. The present disclosure is intended to include all combinations of these technical solutions, which are not listed one by one due to space limitations.

[0149] In a more specific embodiment, the present disclosure provides technical solution 1, which refers to a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof:

[0150]

[0151] in:

[0152] Ring A is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group or C 6-10 Aryl;

[0153] Ring B is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0154] L1 is selected from the group consisting of bonds, -O-, -C(O)-, -CR'R”-, -CR'R”-CR'R”-, or -CR’R”-CR’R”-CR’R”-;

[0155] L2 is selected from the group consisting of bonds, -C(O)-, -CR'R”-, -CR'R”-CR'R”-, or -CR’R”-CR’R”-CR’R”-;

[0156] Y is selected from O, S, NH or CH2;

[0157] R1 is selected from H, -C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0158] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0159] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0160] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0161] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0162] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0163] m = 0, 1, 2, 3, 4 or 5;

[0164] n = 0, 1, 2, 3 or 4;

[0165] p = 0, 1, 2, 3, 4, 5, 6, 7 or 8;

[0166] q = 0, 1, 2, 3, 4 or 5;

[0167] And among them,

[0168] R' and R" are each independently selected from H, halogen, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0169] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0170] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0171] Among them, Y, R1, R2, R s1 , R s2 , R s3 and R s4 Each of which is optionally substituted with 1, 2 or 3 R groups, wherein R is independently selected from H, -OH, halogen, -NO2, carbonyl, -L-CN, -L-OR a 、-L-SR a 、-L-NR b R c 、-LC(O)R a 、-LC(S)R a 、-LC(O)OR a 、-LC(S)OR a 、-LC(O)-NRb R c 、-LC(S)-NR b R c 、-LOC(O)R a 、-LOC(S)R a 、-LN(R b )-C(O)-R a 、-LN(R b )-C(S)-R a 、-LS(O) x R a 、-LS(O) x OR a 、-LS(O) x NR b R c 、-LN(R b )-S(O) x -R a 、-LN(R b )-S(O) x -NR b R c 、-LN(R b )-C(O)OR a 、-LN(R b )-C(S)OR a 、-LOC 1-6 Alkylene-OR a 、-LC(O)-C 1-6 Alkylene-NR b R c 、-LN(R b )-C(O)-NR b R c 、-LN(R b )-C(S)-NR b R c 、-LOC(O)-NR b R c 、-LOC(S)-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl; wherein the C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl are each further optionally substituted with one or more of the following groups:

[0172] -L-CN, -NO2, carbonyl, -L-OR a 、-L-SR a 、-L-NR b R c 、-LC(O)R a 、-LC(S)R a 、-LC(O)OR a 、-LC(S)OR a 、-LC(O)-NR b R c 、-LC(S)-NR b R c 、-LOC(O)R a 、-LOC(S)R a 、-LN(R b )-C(O)-R a 、-LN(R b )-C(S)-R a 、-LS(O) x R a 、-LS(O) x OR a 、-LS(O) x NR b R c 、-LN(R b )-S(O) x -R a 、-LN(R b )-S(O) x -NR b R c 、-LN(R b )-C(O)OR a 、-LN(R b )-C(S)OR a 、-LOC 1-6 Alkylene-OR a 、-LC(O)-C 1-6 Alkylene-NR b R c 、-LN(R b )-C(O)-NR b R c 、-LN(R b)-C(S)-NR b R c 、-LOC(O)-NR b R c or-LOC(S)-NR b R c ;

[0173] L is selected from chemical bonds, -C 1-6 Alkylene-, -C 2-6 Alkenylene- or -C 2-6 Alkynylidene-;

[0174] x=0, 1 or 2.

[0175] In a more specific embodiment, the present disclosure provides Technical Scheme 2, which refers to the compound of formula (I) of Technical Scheme 1, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein R2 is H.

[0176] In a more specific embodiment, the present disclosure provides technical solution 3, which refers to the compound of formula (I) of technical solution 1 or 2, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein R1 is a group other than H.

[0177] In a more specific embodiment, the technical solution 4 provided by the present disclosure refers to the compound of formula (I) of any one of the technical solutions 1 to 3, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotope variant, and mixtures thereof, wherein q=1, 2, 3, 4 or 5, and R s4 At least one of halogen or C l-6 Halogenated alkyl.

[0178] In a more specific embodiment, the present disclosure provides technical solution 5, which refers to the compound of formula (I) of any one of technical solutions 1 to 4, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein m=0, 1, 2 or 3, R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NRb R c , C 1-6 Alkyl or C 1-6 Halogenated alkyl.

[0179] In a more specific embodiment, the present disclosure provides technical solution 6, which refers to the compound of formula (I) of any one of technical solutions 1 to 5, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein p=0, 1 or 2, R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl or C 1-6 Halogenated alkyl.

[0180] In a more specific embodiment, the present disclosure provides technical solution 7, which refers to a compound of formula (I) of any one of technical solutions 1-6, or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein Y is O.

[0181] In a more specific embodiment, the present disclosure provides Technical Scheme 8, which refers to a compound of formula (I) of any one of Technical Schemes 1-7, or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein L2 is -C(O)-.

[0182] In a more specific embodiment, the present disclosure provides technical solution 9, which refers to the compound of formula (I) of any one of technical solutions 1 to 8, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein ring A is selected from the following:

[0183]

[0184] In a more specific embodiment, the present disclosure provides technical solution 10, which refers to the compound of formula (I) of any one of technical solutions 1 to 9, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and mixtures thereof, wherein ring B is selected from the following:

[0185]

[0186] Preferably, wherein Ring B is selected from the following:

[0187]

[0188] In a more specific embodiment, the present disclosure provides technical solution 11, which refers to the compound of formula (I) of any one of technical solutions 1 to 10, which is a compound of formula (II-1) to (II-4):

[0189]

[0190]

[0191] in:

[0192] X is selected from O, S, NH or CH2;

[0193] R3 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0194] R4 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0195] Alternatively, R3 and R4 are connected to form C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0196] R5 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0197] R6 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0198] Alternatively, R5 and R4 are connected to form C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; and

[0199] The other variables are as defined in any one of technical solutions 1 to 10;

[0200] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0201] In a more specific embodiment, the present disclosure provides technical solution 12, which refers to the compound of formula (I) of any one of technical solutions 1 to 10, which is a compound of formula (III-1) to (III-3):

[0202]

[0203]

[0204] Wherein, the variables are as defined in any one of technical solutions 1 to 10;

[0205] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0206] In a more specific embodiment, the present disclosure provides technical solution 13, which refers to the compound of formula (I) of any one of technical solutions 1 to 10, which is a compound of formula (IV-1) to (IV-3):

[0207]

[0208] in:

[0209] X is selected from O, S or NH;

[0210] R4 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0211] R5 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0212] R6 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0213] Alternatively, R5 and R4 are connected to form C 6-10 aryl or 5- to 10-membered heteroaryl; and

[0214] The other variables are as defined in any one of technical solutions 1 to 10;

[0215] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0216] In a more specific embodiment, the present disclosure provides technical solution 14, which refers to the compound of formula (I) of any one of technical solutions 1 to 10, which is a compound of formula (III-1):

[0217]

[0218] in,

[0219] Ring B is a 5- to 10-membered heteroaryl group;

[0220] L1 is the key;

[0221] L2 is selected from a bond, -C(O)- or -CR'R"-;

[0222] Y is selected from O, S or NH;

[0223] R1 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0224] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0225] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0226] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0227] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0228] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0229] m = 0, 1, 2 or 3;

[0230] n = 0, 1, 2 or 3;

[0231] p = 0, 1, 2 or 3;

[0232] q = 0, 1, 2 or 3;

[0233] R' and R" are each independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0234] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0235] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0236] Optionally,

[0237] Ring B is selected from the following:

[0238]

[0239] L1 is the key;

[0240] L2 is -C(O)-;

[0241] Y is O;

[0242] R1 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0243] R2 is H;

[0244] R s1 Selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0245] R s2 is H;

[0246] R s3 is H;

[0247] R s4 is H;

[0248] m = 0, 1 or 2;

[0249] n = 0, 1 or 2;

[0250] p = 0, 1 or 2;

[0251] q = 0, 1 or 2;

[0252] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0253] In a more specific embodiment, the present disclosure provides technical solution 15, which refers to a compound of formula (I) according to any one of technical solutions 1 to 10, which is a compound of formula (III-2):

[0254]

[0255] in,

[0256] Ring B is a 5- to 10-membered heteroaryl group;

[0257] L1 is the key;

[0258] L2 is selected from a bond, -C(O)- or -CR'R"-;

[0259] Y is selected from O, S or NH;

[0260] R1 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0261] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0262] R s1Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0263] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0264] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0265] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0266] m = 0, 1, 2 or 3;

[0267] n = 0, 1, 2 or 3;

[0268] p = 0, 1, 2 or 3;

[0269] q = 0, 1, 2 or 3;

[0270] R' and R" are each independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0271] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0272] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0273] Optionally,

[0274] Ring B is selected from the following:

[0275]

[0276] L1 is the key;

[0277] L2 is -C(O)-;

[0278] Y is O;

[0279] R1 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0280] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0281] R s1 is selected from H or halogen;

[0282] R s2 is H;

[0283] R s3 is H;

[0284] R s4 is H;

[0285] m = 0, 1 or 2;

[0286] n = 0, 1 or 2;

[0287] p = 0, 1 or 2;

[0288] q = 0, 1 or 2;

[0289] Optionally,

[0290] Ring B is a 5- to 6-membered heteroaryl group;

[0291] L1 is the key;

[0292] L2 is selected from a bond, -C(O)- or -CR'R"-;

[0293] Y is selected from O, S or NH;

[0294] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0295] R2 is H;

[0296] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0297] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0298] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0299] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0300] m = 0, 1, 2 or 3;

[0301] n = 0, 1, 2 or 3;

[0302] p = 0, 1, 2 or 3;

[0303] q = 0, 1, 2 or 3;

[0304] R a Independently selected from H, C 1-6 Alkyl, C 1-6Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0305] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0306] Optionally,

[0307] Ring B is selected from the following:

[0308]

[0309] L1 is the key;

[0310] L2 is -C(O)-;

[0311] Y is O;

[0312] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0313] R2 is H;

[0314] R s1 is selected from H or halogen;

[0315] R s2 is H;

[0316] R s3 is H;

[0317] R s4 is H;

[0318] m = 0, 1 or 2;

[0319] n = 0, 1 or 2;

[0320] p = 0, 1 or 2;

[0321] q = 0, 1 or 2;

[0322] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0323] In a more specific embodiment, the present disclosure provides technical solution 16, which refers to the compound of formula (I) of any one of technical solutions 1 to 10, which is a compound of formula (III-3):

[0324]

[0325] in:

[0326] Ring B is a 5- to 10-membered heteroaryl group;

[0327] L1 is -CR'R”-, -CR'R”-CR'R”- or -CR’R”-CR’R”-CR’R”-;

[0328] L2 is selected from a bond, -C(O)- or -CR'R"-;

[0329] Y is selected from O, S or NH;

[0330] R1 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0331] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0332] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0333] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0334] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C1-6 Haloalkyl;

[0335] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0336] m = 0, 1, 2 or 3;

[0337] n = 0, 1, 2 or 3;

[0338] p = 0, 1, 2 or 3;

[0339] q = 0, 1, 2 or 3;

[0340] R' and R" are each independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0341] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0342] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0343] Optionally,

[0344] Ring B is selected from the following:

[0345]

[0346] L1 is -CR'R"-;

[0347] L2 is -C(O)-;

[0348] Y is O;

[0349] R1 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0350] R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0351] R s1 Selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0352] R s2 is H;

[0353] R s3 is H or halogen;

[0354] R s4 is H;

[0355] m = 0, 1 or 2;

[0356] n = 0, 1 or 2;

[0357] p = 0, 1 or 2;

[0358] q = 0, 1 or 2;

[0359] R' and R" are each independently selected from H or halogen;

[0360] Optionally,

[0361] Ring B is a 5- to 10-membered heteroaryl group;

[0362] L1 is the key;

[0363] L2 is selected from a bond, -C(O)- or -CR'R"-;

[0364] Y is selected from O, S or NH;

[0365] R1 is H;

[0366] R2 is H;

[0367] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0368] R s2 Selected from H, halogen, -CN, -NO2, -ORa 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0369] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0370] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0371] m = 0, 1, 2 or 3;

[0372] n = 0, 1, 2 or 3;

[0373] p = 0, 1, 2 or 3;

[0374] q = 0, 1, 2 or 3;

[0375] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0376] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0377] Optionally,

[0378] Ring B is selected from the following:

[0379]

[0380] L1 is the key;

[0381] L2 is -C(O)-;

[0382] Y is O;

[0383] R1 is H;

[0384] R2 is H;

[0385] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0386] R s2 is H;

[0387] R s3 is H;

[0388] R s4 is H;

[0389] m = 0, 1 or 2;

[0390] n = 0, 1 or 2;

[0391] p = 0, 1 or 2;

[0392] q = 0, 1 or 2;

[0393] R a Independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0394] R b and R c Each independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0395] Optionally,

[0396] Ring B is a 5- to 6-membered heteroaryl group;

[0397] L1 is -CR'R”-, -CR'R”-CR'R”- or -CR’R”-CR’R”-CR’R”-;

[0398] L2 is selected from a bond, -C(O)- or -CR'R"-;

[0399] Y is selected from O, S or NH;

[0400] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0401] R2 is H;

[0402] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0403] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0404] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0405] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0406] m = 0, 1, 2 or 3;

[0407] n = 0, 1, 2 or 3;

[0408] p = 0, 1, 2 or 3;

[0409] q = 0, 1, 2 or 3;

[0410] R' and R" are each independently selected from H, halogen, C 1-6 Alkyl or C 1-6Haloalkyl;

[0411] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0412] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0413] Optionally,

[0414] Ring B is selected from the following:

[0415]

[0416] L1 is -CR'R"-;

[0417] L2 is -C(O)-;

[0418] Y is O;

[0419] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0420] R2 is H;

[0421] R s1 is selected from H or halogen;

[0422] R s2 is H;

[0423] R s3 is H or halogen;

[0424] R s4 is H;

[0425] m = 0, 1 or 2;

[0426] n = 0, 1 or 2;

[0427] p = 0, 1 or 2;

[0428] q = 0, 1 or 2;

[0429] R' and R" are each independently selected from H or halogen;

[0430] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0431] In a more specific embodiment, the present disclosure provides technical solution 17, which refers to the compound of formula (I) of any one of technical solutions 1 to 10, which is a compound of formula (IV-1):

[0432]

[0433] in,

[0434] X is selected from O, S or NH;

[0435] R4, R5 and R6 are linked together with the atoms to which they are attached to form C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0436] L1 is the key;

[0437] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0438] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0439] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0440] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0441] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0442] m = 0, 1, 2 or 3;

[0443] n = 0, 1, 2 or 3;

[0444] p = 0, 1, 2 or 3;

[0445] q = 0, 1, 2 or 3;

[0446] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0447] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0448] Optionally,

[0449] X is NH;

[0450] R4, R5 and R6 are joined together with the atoms to which they are attached to form a phenyl group;

[0451] L1 is the key;

[0452] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0453] R s1 is selected from H or halogen;

[0454] R s2 is H;

[0455] R s3 is H;

[0456] R s4 is H;

[0457] m = 0, 1 or 2;

[0458] n = 0, 1 or 2;

[0459] p = 0, 1 or 2;

[0460] q = 0, 1 or 2;

[0461] Optionally,

[0462] X is selected from O, S or NH;

[0463] L1 is the key;

[0464] R1 is H;

[0465] R4 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0466] R5 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0467] R6 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0468] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0469] R s2 Selected from H, halogen, -CN, -NO2, -OR a、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0470] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0471] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0472] m = 0, 1, 2 or 3;

[0473] n = 0, 1, 2 or 3;

[0474] p = 0, 1, 2 or 3;

[0475] q = 0, 1, 2 or 3;

[0476] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0477] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0478] Optionally,

[0479] X is NH;

[0480] L1 is the key;

[0481] R1 is H;

[0482] R4 is selected from H or halogen;

[0483] R5 is selected from H or halogen;

[0484] R6 is selected from H or halogen;

[0485] R s1 Selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0486] R s2 is H;

[0487] R s3 is H;

[0488] R s4 is H;

[0489] m = 0, 1 or 2;

[0490] n = 0, 1 or 2;

[0491] p = 0, 1 or 2;

[0492] q = 0, 1 or 2;

[0493] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0494] In a more specific embodiment, the present disclosure provides technical solution 18, which refers to a compound of formula (I) according to any one of technical solutions 1 to 10, which is a compound of formula (IV-2):

[0495]

[0496] X is selected from O, S or NH;

[0497] R4, R5 and R6 are linked together with the atoms to which they are attached to form C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0498] L1 is the key;

[0499] R1 is selected from H, C 1-6 Alkyl or C 1-6 haloalkyl; optionally, R1 is H;

[0500] R s1Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0501] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0502] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0503] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0504] m = 0, 1, 2 or 3;

[0505] n = 0, 1, 2 or 3;

[0506] p = 0, 1, 2 or 3;

[0507] q = 0, 1, 2 or 3;

[0508] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0509] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0510] Optionally,

[0511] X is NH;

[0512] R4, R5 and R6 are joined together with the atoms to which they are attached to form a phenyl group;

[0513] L1 is the key;

[0514] R1 is selected from H, C 1-6 Alkyl or C 1-6 haloalkyl; optionally, R1 is H;

[0515] R s1 is selected from H or halogen;

[0516] R s2 is H;

[0517] R s3 is H;

[0518] R s4 is H;

[0519] m = 0, 1 or 2;

[0520] n = 0, 1 or 2;

[0521] p = 0, 1 or 2;

[0522] q = 0, 1 or 2;

[0523] Optionally,

[0524] X is selected from O, S or NH;

[0525] L1 is the key;

[0526] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0527] R4 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0528] R5 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0529] R6 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0530] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0531] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0532] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0533] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0534] m = 0, 1, 2 or 3;

[0535] n = 0, 1, 2 or 3;

[0536] p = 0, 1, 2 or 3;

[0537] q = 0, 1, 2 or 3;

[0538] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0539] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0540] Optionally,

[0541] X is O;

[0542] L1 is the key;

[0543] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0544] R4 is selected from H or halogen;

[0545] R5 is selected from H or halogen;

[0546] R6 is selected from H or halogen;

[0547] R s1 is selected from H or halogen;

[0548] R s2 is H;

[0549] R s3 is H;

[0550] R s4 is H;

[0551] m = 0, 1 or 2;

[0552] n = 0, 1 or 2;

[0553] p = 0, 1 or 2;

[0554] q = 0, 1 or 2;

[0555] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0556] In a more specific embodiment, the present disclosure provides technical solution 19, which refers to a compound of formula (I) according to any one of technical solutions 1 to 10, which is a compound of formula (IV-3):

[0557]

[0558] in,

[0559] X is selected from O, S or NH;

[0560] R4, R5 and R6 are linked together with the atoms to which they are attached to form C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0561] L1 is -CR'R”-, -CR'R”-CR'R”- or -CR’R”-CR’R”-CR’R”-;

[0562] R1 is H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0563] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0564] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0565] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0566] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0567] m = 0, 1, 2 or 3;

[0568] n = 0, 1, 2 or 3;

[0569] p = 0, 1, 2 or 3;

[0570] q = 0, 1, 2 or 3;

[0571] R' and R" are each independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0572] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0573] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0574] Optionally,

[0575] X is NH;

[0576] R4, R5 and R6 are joined together with the atoms to which they are attached to form a phenyl group;

[0577] L1 is -CR'R"-;

[0578] R1 is H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0579] R s1 Selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0580] R s2 is H;

[0581] R s3 is H or halogen;

[0582] R s4 is H;

[0583] m = 0, 1 or 2;

[0584] n = 0, 1 or 2;

[0585] p = 0, 1 or 2;

[0586] q = 0, 1 or 2;

[0587] R' and R" are each independently selected from H or halogen;

[0588] Optionally,

[0589] X is selected from O, S or NH;

[0590] L1 is the key;

[0591] R1 is H;

[0592] R4 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0593] R5 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0594] R6 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0595] Or R4, R5 and R6 are linked together with the atoms to which they are attached to form C6-10 Aryl or 5- to 10-membered heteroaryl;

[0596] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0597] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0598] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0599] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0600] m = 0, 1, 2 or 3;

[0601] n = 0, 1, 2 or 3;

[0602] p = 0, 1, 2 or 3;

[0603] q = 0, 1, 2 or 3;

[0604] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0605] Rb and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0606] Optionally,

[0607] X is NH;

[0608] L1 is the key;

[0609] R1 is H;

[0610] R4 is selected from H or halogen;

[0611] R5 is selected from H or halogen;

[0612] R6 is selected from H or halogen;

[0613] or R4, R5 and R6 are joined together with the atoms to which they are attached to form a phenyl group;

[0614] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0615] R s2 is H;

[0616] R s3 is H;

[0617] R s4 is H;

[0618] m = 0, 1 or 2;

[0619] n = 0, 1 or 2;

[0620] p = 0, 1 or 2;

[0621] q = 0, 1 or 2;

[0622] R a Independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0623] R b and R c Each independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0624] Optionally,

[0625] X is selected from O, S or NH;

[0626] L1 is -CR'R”-, -CR'R”-CR'R”- or -CR’R”-CR’R”-CR’R”-;

[0627] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0628] R4 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0629] R5 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0630] R6 is selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0631] R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0632] R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b Rc , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0633] R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0634] R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c , C 1-6 Alkyl or C 1-6 Haloalkyl;

[0635] m = 0, 1, 2 or 3;

[0636] n = 0, 1, 2 or 3;

[0637] p = 0, 1, 2 or 3;

[0638] q = 0, 1, 2 or 3;

[0639] R' and R" are each independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0640] R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl;

[0641] R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group;

[0642] Optionally,

[0643] X is O;

[0644] L1 is -CR'R"-;

[0645] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl;

[0646] R4 is selected from H or halogen;

[0647] R5 is selected from H or halogen;

[0648] R6 is selected from H or halogen;

[0649] R s1 is selected from H or halogen;

[0650] R s2 is H;

[0651] R s3 is H or halogen;

[0652] R s4 is H;

[0653] m = 0, 1 or 2;

[0654] n = 0, 1 or 2;

[0655] p = 0, 1 or 2;

[0656] q = 0, 1 or 2;

[0657] R' and R" are each independently selected from H or halogen;

[0658] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0659] The disclosed compounds may include one or more asymmetric centers, and therefore may exist in a variety of stereoisomeric forms, for example, enantiomers and / or diastereoisomeric forms. For example, the disclosed compounds may be individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers), or may be in the form of a mixture of stereoisomers, including a racemic mixture and a mixture enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including: chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0660] Those skilled in the art will appreciate that an organic compound can form a complex with a solvent in which it reacts or from which it precipitates or crystallizes. These complexes are referred to as "solvates". When the solvent is water, the complex is referred to as a "hydrate". The present disclosure encompasses all solvates of the disclosed compounds.

[0661] The term "solvate" refers to a form of a compound or its salt that is combined with a solvent, usually formed by a solvent decomposition reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, ether, etc. The compounds described herein can be prepared, for example, in a crystalline form and can be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric solvates and non-stoichiometric solvates. In some cases, the solvate will be able to separate, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" includes solvates in solution and separable solvates. Representative solvates include hydrates, ethanolates and methanolates.

[0662] The term "hydrate" refers to a compound that is combined with water. Generally, the ratio of the number of water molecules contained in the hydrate of a compound to the number of molecules of the compound in the hydrate is determined. Therefore, the hydrate of a compound can be represented by, for example, the general formula R xH2O, where R is the compound and x is a number greater than 0. A given compound can form more than one type of hydrate, including, for example, a monohydrate (x is 1), a lower hydrate (x is a number greater than 0 and less than 1, for example, a hemihydrate (R·0.5H2O)) and a polyhydrate (x is a number greater than 1, for example, a dihydrate (R·2H2O) and a hexahydrate (R·6H2O)).

[0663] The disclosed compounds can be in amorphous or crystalline form (polymorph). In addition, the disclosed compounds can exist in one or more crystalline forms. Therefore, the present disclosure includes all amorphous or crystalline forms of the disclosed compounds within its scope. The term "polymorph" refers to the crystalline form (or its salt, hydrate or solvate) of a compound with a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms generally have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, photoelectric properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors may result in one crystalline form being dominant. Various polymorphs of a compound can be prepared by crystallization under different conditions.

[0664] The present disclosure also includes isotopically labeled compounds, which are identical to those described in formula (I), but one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number commonly found in nature. Examples of isotopes that can be introduced into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, for example 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of the present disclosure containing the above isotopes and / or other isotopes of other atoms, their prodrugs, and pharmaceutically acceptable salts of the compounds or prodrugs are within the scope of the present disclosure. Certain isotope-labeled compounds of the present disclosure, such as those introduced with radioactive isotopes (e.g. 3 H and 14 C) can be used in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred because they are easy to prepare and detect. Furthermore, substitution with heavier isotopes, such as deuterium (i.e. 2 H), may be preferred in some cases because greater metabolic stability may provide therapeutic benefits, such as extended in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of the present disclosure of formula (I) and their prodrugs can generally be prepared by replacing non-isotopically labeled reagents with readily available isotopically labeled reagents when performing the processes disclosed in the following schemes and / or the examples and preparations.

[0665] In addition, prodrugs are also included in the context of the present disclosure. The term "prodrug" as used herein refers to a compound that is converted into its active form having a medical effect in vivo, for example, by hydrolysis in the blood. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each of which is incorporated herein by reference.

[0666] Prodrugs are any covalently bonded compounds of the present invention that release the parent compound in vivo when such prodrugs are administered to a patient. Prodrugs are generally prepared by modifying functional groups, the modification being carried out in such a way that the modification can be cleaved to produce the parent compound by conventional manipulation or in vivo. Prodrugs include, for example, compounds of the present invention in which a hydroxyl, amino or sulfhydryl group is bonded to any group, which can be cleaved to form a hydroxyl, amino or sulfhydryl group when administered to a patient. Therefore, representative examples of prodrugs include, but are not limited to, acetate / amide, formate / amide and benzoate / amide derivatives of hydroxyl, sulfhydryl and amino functional groups of compounds of formula (I). In addition, in the case of carboxylic acid (-COOH), esters such as methyl esters, ethyl esters, etc. can be used. Esters themselves can be active and / or can be hydrolyzed under human body conditions. Suitable pharmaceutically acceptable in vivo hydrolyzable ester groups include those groups that are easily decomposed in the human body to release the parent acid or its salt.

[0667] The present disclosure also provides a pharmaceutical preparation comprising a therapeutically effective amount of a compound of formula (I) or a therapeutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient thereof. All of these forms belong to the present disclosure.

[0668] Preferred compounds disclosed herein include, but are not limited to, the following compounds:

[0669]

[0670]

[0671]

[0672]

[0673] or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof.

[0674] Pharmaceutical compositions, preparations and kits

[0675] On the other hand, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present disclosure. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present disclosure. In some embodiments, the pharmaceutical composition comprises a preventive effective amount of a compound of the present disclosure.

[0676] The pharmaceutically acceptable excipient used in the present disclosure refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated together. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the compositions of the present disclosure include (but are not limited to) ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum proteins), buffer substances (e.g., phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (e.g., protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.

[0677] The present disclosure also includes a kit (e.g., a pharmaceutical package). The kit provided may include a compound of the present disclosure, other therapeutic agents, and a first and second container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispersible package or other suitable container) containing the compound of the present disclosure and other therapeutic agents. In some embodiments, the kit provided may also optionally include a third container containing a pharmaceutical excipient for diluting or suspending the compound of the present disclosure and / or other therapeutic agents. In some embodiments, the compound of the present disclosure and other therapeutic agents provided in the first container and the second container are combined to form a unit dosage form.

[0678] Drug administration

[0679] The pharmaceutical composition provided by the present disclosure can be administered by many routes, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration, rectal administration, nasal administration, oral administration, vaginal administration, administration by implant or other modes of administration. For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial cavity administration, intrasternal administration, intrathecal administration, intralesional administration, and intracranial injection or infusion techniques.

[0680] Generally, an effective amount of the compounds provided herein is administered. The amount of the compound actually administered can be determined by a physician according to the relevant circumstances, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.

[0681] When used to prevent the conditions described in the present disclosure, the compounds provided herein are administered to a subject at risk of developing the condition, typically based on the advice of a physician and under the supervision of a physician, at dosage levels as described above. Subjects at risk of developing a specific condition typically include those with a family history of the condition, or those identified by genetic testing or screening as being particularly susceptible to developing the condition.

[0682] The pharmaceutical compositions provided herein can also be administered over a long period of time ("chronic administration"). Chronic administration refers to administration of a compound or a pharmaceutical composition thereof over a long period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration may continue indefinitely, e.g., for the rest of the subject's life. In some embodiments, chronic administration is intended to provide a constant level of the compound in the blood over a long period of time, e.g., within a therapeutic window.

[0683] Various methods of administration can be used to further deliver the pharmaceutical composition of the present disclosure. For example, in some embodiments, the pharmaceutical composition can be administered by push injection, for example, so that the concentration of the compound in the blood is increased to an effective level. The push dose depends on the target systemic level of the active component through the body, for example, the intramuscular or subcutaneous push dose slowly releases the active component, and the push injection (for example, by IV intravenous drip) delivered directly to the vein can be delivered more quickly, so that the concentration of the active component in the blood is quickly increased to an effective level. In other embodiments, the pharmaceutical composition can be given in the form of continuous infusion, for example, by IV intravenous drip, so as to provide a steady-state concentration of the active component in the subject's body. In addition, in other embodiments, the pharmaceutical composition of the push dose can be first given, and then continuous infusion.

[0684] Oral compositions can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more generally, in order to facilitate accurate dosing, the composition is provided in unit dosage form. The term "unit dosage form" refers to a physical discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active ingredients suitable for producing the desired therapeutic effect and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. in the case of solid compositions. In such compositions, the compound is usually a relatively small component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), and the remainder is various carriers or excipients and processing aids useful for forming the desired administration form.

[0685] For oral dosage, a representative regimen is one to five oral doses per day, especially two to four oral doses, typically three oral doses. Using these dosage modes, each dose provides about 0.01 to about 20 mg / kg of the disclosed compound, and preferred doses each provide about 0.1 to about 10 mg / kg, especially about 1 to about 5 mg / kg.

[0686] In order to provide blood levels similar to those using an injectable dose, or lower blood levels than using an injectable dose, a transdermal dose is generally selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.

[0687] From about 1 to about 120 hours, especially 24 to 96 hours, the injected dosage level is in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour. In order to obtain sufficient steady state levels, a preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be given. For a 40 to 80 kg human patient, the maximum total dose cannot exceed about 2 g / day.

[0688] Liquid forms suitable for oral administration may include suitable aqueous or non-aqueous carriers, buffers, suspending and dispersing agents, colorants, flavoring agents, etc. Solid forms may include, for example, any of the following components, or compounds of a similar nature: binders, such as microcrystalline cellulose, tragacanth, or gelatin; excipients, such as starch or lactose; disintegrants, such as alginic acid, Primogel, or corn starch; lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or flavoring agents, such as peppermint, methyl salicylate, or orange flavoring.

[0689] Injectable compositions are typically based on injectable sterile saline or phosphate buffered saline, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, and the remainder is an injectable excipient, etc.

[0690] Typically, transdermal compositions are formulated as topical ointments or creams containing active ingredients. When formulated as an ointment, the active ingredient is typically combined with a paraffin or water-miscible ointment base. Alternatively, the active ingredient can be formulated into an ointment with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components for enhancing the stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by the present disclosure.

[0691] The disclosed compounds may also be administered by transdermal means. Thus, transdermal administration may be achieved using patches of the reservoir or porous membrane type, or a variety of solid matrices.

[0692] The above components for oral administration, injection or topical administration are representative only. Other materials and processing techniques are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[0693] The disclosed compounds can also be administered in sustained release form, or from a sustained release delivery system. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0694] The present disclosure also relates to pharmaceutically acceptable formulations of the disclosed compounds. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β- and γ-cyclodextrins consisting of 6, 7 and 8 α-1,4-linked glucose units, respectively, which optionally include one or more substituents on the linked sugar moiety, including but not limited to: methylated, hydroxyalkylated, acylated and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, for example, sulfobutyl ether β-cyclodextrin, also known as Captisol. See, for example, US5,376,645. In some embodiments, the formulation includes hexapropyl-β-cyclodextrin (e.g., in water, 10-50%).

[0695] Combination therapy

[0696] The disclosed compounds may also be administered with other therapeutic agents (eg, cholesterol-lowering agents, fibrates and hypolipidemic agents, antidiabetic agents, antihypertensive agents, and angiotensin converting enzyme (ACE) inhibitors).

[0697] In some embodiments, the other therapeutic agent is a cholesterol-lowering agent. Non-limiting examples of cholesterol-lowering agents are: atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, ezetimibe, and a combination of ezetimibe / simvastatin

[0698] In some embodiments, the other therapeutic agent is a fibrate or a hypolipidemic agent. Non-limiting examples of fibrates or hypolipidemic agents are: acifuran, acipimox, beclofibrate, bezafibrate, binifibrate, ciprofibrate, clofibrate, colesevelam, gemfibrozil, fenoflbrate, methyllinoleamide, niacin, and ronafibrate.

[0699] In some embodiments, the other therapeutic agent is a DPP-IV inhibitor as an antidiabetic agent. Non-limiting examples of DPP-IV inhibitors as antidiabetic agents are: sitagliptin, saxagliptin, vildagliptin, linagliptin, dulagliptin, gemagliptin, and alogliptin.

[0700] In some embodiments, the other therapeutic agent is an antidiabetic agent other than a DPP-IV inhibitor. Non-limiting examples of antidiabetic agents are: acarbose, epalrestat, exenatide, glimepiride, liraglutide, metformin, miglitol, mitiglinide, nateglinide, pioglitazone, pramlintide, repaglinide, rosiglitazone, torestat, troglitazone and voglibose.

[0701] In some embodiments, the other therapeutic agent is an antihypertensive agent. Non-limiting examples of antihypertensive agents include: alacepril, alfuzosin, aliskiren, amlodipine besylate, amosulolol, aranidipine, arotinolol HCl, azelnidipine, barnidipine hydrochloride, benazepril hydrochloride, benidipine hydrochloride, betaxolol HCl, bevantolol HCl, bisoprolol fumarate, bopindolol, bosentan, budrazine, bunazosin HCl, candesartan, captopril, carvedilol, celiprolol HCl, cillotanin, cilazapril, cilnidipine, clevidipine, Delapril, dilevolol, doxazosin mesylate, efonidipine, enalapril maleate, enalaprilat, eplerenone, eprosartan, felodipine, fenoldopam mesylate, fosinopril sodium, guanadil sulfate, imidapril HCl, irbesartan, isradipine, ketanserin, lacidipine, lercanidipine, lisinopril, losartan, manidipine hydrochloride, miradil hydrochloride, moxonidine, nebivolol, nilvadipine, nipradirol, nisoldipine, olmesartan medoxomil medoxomil), perindopril, pinacidil, quinapril, ramipril, rilmenidine, spirapril HCl, telmisartan, temocarpil, terazosin HCl, tertalol HCl, tiamenidine HCl, tilisolol hydrochloride, trandolapril, treprostinil sodium, trimazosin HCl, valsartan, and zofenopril calcium.

[0702] In other embodiments, suitable angiotensin converting enzyme (ACE) inhibitors for use in the above combination therapy include, but are not limited to, enalapril, ramipril, quinapril, perindopril, lisinopril, imidapril, zofenopril, trandolapril, fosinopril, and captopril.

[0703] Example

[0704] The following examples are provided to provide those skilled in the art with a complete disclosure and description of how to perform, prepare and evaluate the methods and compounds claimed herein and are intended to be illustrative only and not to limit the scope of the invention.

[0705] Schemes for the preparation of compounds disclosed herein are shown below.

[0706] Scheme 1: General synthetic scheme for preparing monoamide intermediates:

[0707]

[0708] According to Scheme 1, N-BOC-iminodiacetic acid was blocked in situ to anhydride 1 (1 equivalent EDCI in DMF) and then treated with amine (1 equivalent in DMF) to give monoamide A.

[0709] Scheme 2: General synthetic process for preparing diamide intermediates

[0710]

[0711] According to Scheme 2, monoamide A is treated with an amine, EDCI and HOBT to give diamide intermediate B.

[0712] Scheme 3: Deprotection of diamide intermediate

[0713]

[0714] According to Scheme 3, N-Boc deprotection of diamide B using 4N HCl-dioxane at room temperature gave the hydrochloride salt of amine C.

[0715] Scheme 4: General synthetic scheme for preparing the disclosed compounds

[0716]

[0717] According to Scheme 4, the disclosed compounds can be prepared by reacting the diamide intermediate with a compound (wherein X can be halogen, aldehyde and carboxylic acid) in the presence of EDCI and HOBT.

[0718] General synthetic process for preparing monoamide intermediates:

[0719] A solution of N-((tert-butoxy)carbonyl)iminodiacetic acid (2.33 g, 10 mmol) in DCM (30 mL) was treated with EDCI (1.98 g, 10.3 mmol) at 25°C. The mixture was stirred at 25°C for 1 h, then the amine (12 mmol) was added and the solution was stirred at 25°C for 20 h. The reaction mixture was poured into 10% HCl (aq) (100 mL), extracted with DCM (100 mL × 2). The organic phase was washed with 10% HCl (aq) (80mL×2) and saturated NaCl (aq) The mixture was washed with (100 mL x 2), dried (MgSO 4 ), filtered, and concentrated in vacuo to afford pure N-((tert-butoxy)-carbonyl)iminodiacetic acid monoamide.

[0720] General process for preparing diamide intermediates

[0721] N-((tert-Butyloxy)-carbonyl)iminodiacetic acid monoamide (4.8 mmol) was dissolved in DCM (15 mL). The solution was treated with amine (1 eq.), EDCI (1.2 eq.), HOBt (1.2 eq.) and Et3N (1.5 eq.). The solution was stirred at 25 °C for 20 h. The mixture was poured into H2O and extracted with DCM (40 mL x 2). The organic phase was washed with saturated NaCl (aq) The resulting product was washed with 1% paraformaldehyde (50 mL x 2), dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by MPLC to give the pure diamide.

[0722] General process for preparing Boc deprotected diamide intermediates

[0723] N'-((tert-Butyloxy)carbonyl)-N,N-disubstituted iminodiacetic acid diamide (2.88 mmol) was dissolved in 4N HCl-dioxane, and the mixture was stirred at 25°C for 1 h. The solvent was removed in vacuo. The residue was purified by MPLC to provide the desired product.

[0724] According to the above process, the following diamide intermediate is obtained:

[0725]

[0726]

[0727] General Process for Preparing Compounds of the Disclosure

[0728] A solution of diamide (0.25 mmol), carboxylic acid (0.25 mmol), EDCI (0.30 mol), HOBt (0.3 mol), Et3N (0.05 mL) and DMF (2 mL) was stirred at 25°C for 20 h. The mixture was poured into 10% HCl. (aq) The organic phase was washed with saturated NaCl (aq) The organic phase was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by MPLC to provide the desired product.

[0729] Preparation of Compound 201-29

[0730]

[0731] Compound 201-29 was prepared using a general process for preparing the disclosed compounds. Specifically, a solution of diamide B5a (112 mg, 0.25 mmol), EDCI (47 mg, 0.30 mmol), HOBT (40 mg, 0.3 mmol) and Et3N (0.05 mL) in DMF (2 mL) was stirred at 25 ° C for 20 h. The mixture was poured into a 10% aqueous HCl solution (10 mL) and extracted with EtOAc (15 mL). The organic phase was washed with a saturated NaCl aqueous solution (2×10 mL). The organic phase was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by MPLC to provide the desired product (129 mg, 85%).

[0732] Some other compounds were prepared according to the synthetic procedures of compounds 201-29, but using different carboxylic acid and diamide intermediates.

[0733] Table 1:

[0734]

[0735]

[0736]

[0737]

[0738]

[0739] Preparation of Compound 201-65

[0740]

[0741] Compounds 201-65 were prepared using the general process for preparing compounds of the present disclosure. Some other compounds were prepared according to the synthetic process of compounds 201-65, but using different carboxylic acids.

[0742] Table 2.

[0743]

[0744]

[0745]

[0746]

[0747] Preparation of Compound 201-74

[0748]

[0749] Compounds 201-74 were prepared using the general process for preparing compounds of the present disclosure. Some other compounds were prepared according to the synthetic process of compounds 201-74, but using different carboxylic acid and diamide intermediates.

[0750] Table 3.

[0751]

[0752]

[0753]

[0754]

[0755]

[0756]

[0757]

[0758]

[0759] Preparation of Compound 201-5

[0760]

[0761] Compound 201-5 was prepared using the general process for preparing compounds of the present disclosure. Some other compounds were prepared according to the synthetic process of compound 201-5, but using different carboxylic acid and diamide intermediates.

[0762] Table 4.

[0763]

[0764]

[0765]

[0766] Alternative general process for preparing the disclosed compounds

[0767] Aldehyde (2mmol) was added to a solution of amine (2mmol) in DCE (5mL) and stirred at room temperature for 15min. NaBH(OAc) 3 (2.5mmol) was added to the resulting mixture and the mixture was stirred at room temperature until TLC showed that the starting aldehyde had completely disappeared. The reaction mixture was quenched with water (10mL) and extracted with CH2Cl2 (3×10mL). The combined extracts were dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by MPLC to provide the desired product.

[0768] Preparation of Compound 201-135

[0769]

[0770] Compounds 201-135 were prepared using the general process for preparing compounds of the present disclosure. Some other compounds were prepared according to the synthetic process of compounds 201-135, but using different aldehyde and diamide intermediates.

[0771] Table 5.

[0772]

[0773]

[0774] Preparation of Compounds 201-255

[0775]

[0776] Compounds 201-255 were prepared using the general process for preparing compounds of the present disclosure. Some other compounds were prepared according to the synthetic process of compounds 201-255, but using different aldehyde and diamide intermediates.

[0777] Table 6:

[0778]

[0779]

[0780]

[0781] Biological Testing

[0782] Materials and methods:

[0783] Cell culture:

[0784] HepG2 cells (ATCC, Cat.: HB-8065) ​​were maintained in growth medium—Eagle's Minimum Essential Medium (Corning, 10-010-CVR), 10% FBS (Gibco, 10099-141), penicillin (100 units / mL), and streptomycin (100 μg / mL). HepG2 cells were incubated at 37°C and 5% CO2.

[0785] Cell viability test

[0786] HepG2 cells were plated at 40,000 cells / well in a black clear-bottom 96-well plate (Corning, 3063) in 100 μL growth medium. After overnight incubation, the medium was replaced with serum-free OptiMEM medium (Gibco, 31985-062) at 90 μL / well. Vehicle, PF-06446846 hydrochloride, berberine, or test compound were added to the medium at 10 μL / well. After 24 hours, the cells were plated with ATP levels in cells were measured using the 2.0 Assay (Promega, G9242).

[0787] ELISA test

[0788] HepG2 cells were plated at 40,000 cells / well in a flat-bottom 96-well plate (Corning, 3599) in 100 μL growth medium. After overnight incubation, the medium was replaced with serum-free OptiMEM medium (Gibco, 31985-062), 90 μL / well. Vehicle, PF-06446846 hydrochloride, berberine or test compound were added to the medium, 10 μL / well. The medium was harvested after 24 hours, and 10 μL of the medium was used for PCSK9 ELISA (R&D Systems, SPC900).

[0789] RNA extraction and reverse transcription quantitative PCR (RT-Q-PCR) analysis

[0790] Cells were cultured in growth medium as described above and treated with vehicle, berberine or test compound for 24 h. RNA was extracted using a total RNA mini kit (Tiangen, Beijing, China) according to the manufacturer's instructions. Reverse transcription was performed using a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific). Quantitative real-time PCR was performed using a reaction mixture containing cDNA, specific primers [PCSK9, 5'-GCTGAGCTGCTCCAGTTTCT-3' (forward) and 5'-AATGGCGTAGACACCCTCAC-3' (reverse); GAPDH, 5'-CATGAGAAGTATGACAACAGCCT-3' (forward) and 5'-AGTCCTTCCACGATACCAAAGT-3' (reverse)] and Maxima SYBR Green / ROX qPCR Master Mix (Thermo Fisher Scientific). PCR amplification was performed in a real-time PCR system. The conditions of real-time PCR were 37°C for 10 min, 95°C for 10 min, 95°C for 15 s, 60°C for 30 s, 72°C for 30 s, 40 cycles. The amount of mRNA in the same sample was normalized to the level of GAPDH.

[0791] Table 7.

[0792]

[0793]

[0794]

[0795] Determination of Dil-LDL uptake

[0796] HepG2 cells were maintained in MEM supplemented with 10% FBS. 4 Cells were seeded at a density of 10 cells in a 96-well black plate and grown to 70-80% confluency. Afterwards, the cells were switched to serum-free Opti-MEM for 1 hour and then incubated with 10 μM berberine or the disclosed compound for 20 h. Then, 20 μg / mL Dil-LDL was added and incubated for another 4 h at 37°C in the dark. The cells were washed thoroughly 3 times with PBS and LDL uptake was measured on a fluorescence plate reader at an excitation wavelength of 520 nm and an emission wavelength of 580 nm.

[0797]

[0798]

[0799] Although the present disclosure has been described in detail with reference to specific preferred embodiments, it cannot be concluded that the specific embodiments of the present disclosure are limited to these descriptions. Those skilled in the art will understand that, without departing from the concept of the present disclosure, several simple deductions or substitutions can be made, which should all be considered to belong to the scope of protection of the present disclosure.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof: in: Ring A is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group or C 6-10 Aryl; Ring B is selected from C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl; L1 is selected from the group consisting of bonds, -O-, -C(O)-, -CR'R”-, -CR'R”-CR'R”-, or -CR’R”-CR’R”-CR’R”-; L2 is selected from the group consisting of bonds, -C(O)-, -CR'R”-, -CR'R”-CR’R”-, or -CR’R”-CR’R”-CR’R”-; Y is selected from O, S, NH or CH2; R1 is selected from H, -C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl; R2 is selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl; R s1 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl; R s2 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl; R s3 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl; R s4 Selected from H, halogen, -CN, -NO2, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl; m = 0, 1, 2, 3, 4 or 5; n = 0, 1, 2, 3 or 4; p = 0, 1, 2, 3, 4, 5, 6, 7 or 8; q = 0, 1, 2, 3, 4 or 5; And among them, R' and R" are each independently selected from H, halogen, -OR a 、-SR a 、-NR b R c 、-C(O)R a 、-C(O)OR a 、-C(O)NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl; R a Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 Aryl or 5- to 10-membered heteroaryl; R b and R c Each independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3 to 7 membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl; or, R b , R c Together with the N atom, it forms a 3- to 7-membered heterocyclic group; Among them, Y, R1, R2, R s1 , R s2 , R s3 and R s4 Each of which is optionally substituted with 1, 2 or 3 R groups, wherein R is independently selected from H, -OH, halogen, -NO2, carbonyl, -L-CN, -L-OR a 、-L-SR a 、-L-NR b R c 、-LC(O)R a 、-LC(S)R a 、-LC(O)OR a 、-LC(S)OR a 、-LC(O)-NR b R c 、-LC(S)-NR b R c 、-LOC(O)R a 、-LOC(S)R a 、-LN(R b )-C(O)-R a 、-LN(R b )-C(S)-R a 、-LS(O) x R a 、-LS(O) x OR a 、-LS(O) x NR b R c 、-LN(R b )-S(O) x -R a 、-LN(R b )-S(O) x -NR b R c 、-LN(R b )-C(O)OR a 、-LN(R b )-C(S)OR a 、-LOC 1-6 Alkylene-OR a 、-LC(O)-C 1-6 Alkylene-NR b R c 、-LN(R b )-C(O)-NR b R c 、-LN(R b )-C(S)-NR b R c 、-LOC(O)-NR b R c 、-LOC(S)-NR b R c , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl; wherein the C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -LC 3-7 Cycloalkyl, -L-3 to 7 membered heterocyclic group, -LC 6-10 Aryl or -L-5 to 10 membered heteroaryl are each further optionally substituted with one or more of the following groups: -L-CN, -NO2, carbonyl, -L-OR a , -L-SR a , -L-NR b R c , -L-C(O)R a , -L-C(S)R a , -L-C(O)OR a , -L-C(S)OR a , -L-C(O)-NR b R c , -L-C(S)-NR b R c , -L-O-C(O)R a , -L-O-C(S)R a , -L-N(R b )-C(O)-R a , -L-N(R b )-C(S)-R a , -L-S(O) x R a , -L-S(O) x OR a , -L-S(O) x NR b R c , -L-N(R b )-S(O) x -R a , -L-N(R b )-S(O) x -NR b R c , -L-N(R b )-C(O)OR a , -L-N(R b )-C(S)OR a , -L-O-C 1-6 alkylene-OR a , -L-C(O)-C 1-6 alkylene-NR b R c , -L-N(R b )-C(O)-NR b R c , -L-N(R b )-C(S)-NR b R c , -L-O-C(O)-NR b R c or -L-O-C(S)-NR b R c ; L is selected from chemical bonds, -C 1-6 Alkylene-, -C 2-6 Alkenylene- or -C 2-6 Alkynylidene-; x=0, 1 or 2.

2. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a pharmaceutically acceptable excipient; optionally, the pharmaceutical composition further comprises one or more other therapeutic agents.

3. Use of a compound according to claim 1 or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof in the preparation of a medicament for treating and / or preventing a PCSK9-mediated disease.

4. The use of claim 3, wherein the PCSK9-mediated disease is selected from the group consisting of atherosclerosis, dyslipidemia, hypertriglyceridemia, hypertension, heart failure, arrhythmia, low HDL level, high LDL level, sudden death, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia (including heterozygous and homozygous familial hypercholesterolemia), stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease, arterial occlusive disease, cerebral arteriosclerosis, cerebrovascular disease, myocardial ischemia, non-alcoholic fatty liver disease (NLLD), non-alcoholic steatohepatitis (NASH) and diabetic autonomic neuropathy.

5. An intermediate compound selected from: